Path-breaking innovations for lung cancer: a revolution in clinical practice
Mario Coccia ()
CERIS Working Paper from Institute for Economic Research on Firms and Growth - Moncalieri (TO) ITALY -NOW- Research Institute on Sustainable Economic Growth - Moncalieri (TO) ITALY
Lung cancer is one of main cause of death worldwide and traditional chemotherapy agents have reached the maturity phase in the treatment of advanced non-small cell lung cancer. The purpose of this paper is to analyse the evolutionary growth of knowledge patterns of vital radical innovations to treat lung cancer, driven by new technological paradigm of the targeted therapy, that have generating a revolution in clinical practice, increasing the overall survival of patients and quality of life. This new scientific pathway has evolving with an allometric process that involves a disproportionate growth of targeted therapy in relation to standard platinum-based chemotherapy alone.
JEL-codes: O33 I1 L65 (search for similar items in EconPapers)
Pages: 26 pages Keywords : Radical Innovation, Technological Paradigm, Clinical Practice, Molecular Biology, Lung Cancer, Targeted Therapy.
New Economics Papers: this item is included in nep-hea and nep-hme
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://www.digibess.it/fedora/repository/object_do ... bess_TO094-00070.pdf (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:csc:cerisp:201201
Access Statistics for this paper
More papers in CERIS Working Paper from Institute for Economic Research on Firms and Growth - Moncalieri (TO) ITALY -NOW- Research Institute on Sustainable Economic Growth - Moncalieri (TO) ITALY Contact information at EDIRC.
Bibliographic data for series maintained by Anna Perin ().